With the volume of procurement continued to go deep, the off-court market or a great change

"Pharmaceutical network industry dynamics" a few days ago, the Shanghai Joint Procurement Office issued the third batch of national centralized volume procurement results, in addition to Ramif fixed flow mark, the remaining 55 generic varieties successfully winning the bid, resulting in 125 selected enterprises, 191 selected drug regulations, the average price reduction of more than 70%, to a high drop of up to 98.7%.
addition to this, the average price of apixaban, otoxepine, finasteride (5mg), Catopri, Megyn, Monrust, Celexib and Tofatib has fallen by more than 90 per cent on average.
To some extent, there are some varieties can be said to have entered the "one point" era, which will directly affect the future production, packaging, distribution and even marketing costs, or the pharmaceutical representative of this position caused a major blow.
In addition to the above situation, in this national quotation, it is more noteworthy that under the fierce competition of domestic pharmaceutical companies, a number of foreign-funded pharmaceutical enterprises either abandoned the election or increased prices, resulting in only 3 varieties selected.
are methylcobalamin of the ingredient, UCB's left ethyl laxitan injection with a strong solution, Pfizer's lynazine tablets, the remaining varieties of foreign companies, such as Lilly, Bayer, AstraZeneone, all retreated.
this can be seen that this round of most of the original pharmaceutical enterprises quoted firmly, basically no intention to reduce the price of winning the bid.
such as Ramif fixed flow mark, is because the original pharmaceutical companies reported more than the collection to the high limit price of 80 times the price.
industry analysts believe that this means that, in the face of the normalization of the national collection, foreign pharmaceutical companies in the market share and price of the choice, or choose the latter.
, the off-court market may become a new battleground for market share among many pharmaceutical companies.
, although the hospital market has long been a major selling ground for prescription drugs.
, with the gradual progress of the volume procurement policy, the unseeded varieties almost lost the country's major public hospital sales market.
in order to restore the market share of the past, many enterprises and varieties have begun to make efforts to sell outside the market.
E.e. Pfizer has already done a re-analysis of the relevant strategy after the collection of tenders, but also made a "one product, two regulations, three dosage forms" strategy to help hospitals establish a reasonable drug use catalog, it is recommended that it retain a national collection of varieties, and then retain a original drug species.
on the one hand, to ensure that medical institutions can complete the task of national collection, on the other hand, when the supply of drugs collected by the state is not available, or high-end patients have the demand for original research drugs, their own varieties can complement the needs of patients.
In general, the sharp price reduction, the increasing cost of health insurance control, public hospitals and medical insurance payment of the drug market will be more and more compressed, which in a great test of enterprise marketing ability, but also will prompt domestic pharmaceutical companies to increase investment in innovation, after all, innovation era, enterprises to survive must continue to research and development, innovation, walking in the forefront, in order to have more competitiveness.